JMJD2 Promotes Acquired Cisplatin Resistance in Non-small Cell Lung Carcinoma Cells

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2019 Apr 11

PMID 30967636

Citations 17

Authors

Lei Duan

Ricardo E Perez

Paul D Chastain 2nd

Mathew T Mathew

Divya Rani Bijukumar

Carl G Maki

Affiliations

Soon will be listed here.

Abstract

Platinum-based drugs such as cisplatin (CP) are the first-line chemotherapy for non-small-cell lung carcinoma (NSCLC). Unfortunately, NSCLC has a low response rate to CP and acquired resistance always occurs. Histone methylation regulates chromatin structure and is implicated in DNA repair. We hypothesize histone methylation regulators are involved in CP resistance. We therefore screened gene expression of known histone methyltransferases and demethylases in three NSCLC cell lines with or without acquired resistance to CP. JMJD2s are a family of histone demethylases that remove tri-methyl groups from H3K9 and H3K36. We found expression of several JMJD2 family genes upregulated in CP-resistant cells, with JMJD2B expression being upregulated in all three CP-resistant NSCLC cell lines. Further analysis showed increased JMJD2 protein expression coincided with decreased H3K9me3 and H3K36me3. Chemical inhibitors of JMJD2-family proteins increased H3K9me3 and H3K36me3 levels and sensitized resistant cells to CP. Mechanistic studies showed that JMJD2 inhibition decreased chromatin association of ATR and Chk1 and inhibited the ATR-Chk1 replication checkpoint. Our results reveal that JMJD2 demethylases are potential therapeutic targets to overcome CP resistance in NSCLC.

Citing Articles

Ribosomal S6 kinase (RSK) plays a critical role in DNA damage response via the phosphorylation of histone lysine demethylase KDM4B.

Wu W, Zhu J, Nihira N, Togashi Y, Goda A, Koike J Breast Cancer Res. 2024; 26(1):146.

PMID: 39434131 PMC: 11492477. DOI: 10.1186/s13058-024-01901-x.

Sponge-derived alkaloid AP-7 as a sensitizer to cisplatin in the treatment of multidrug-resistant NSCLC via Chk1-dependent mechanisms.

Guan L, Liao Y, Cao M, Liu L, Xue H, Zhu H Front Pharmacol. 2024; 15:1423684.

PMID: 39045048 PMC: 11263074. DOI: 10.3389/fphar.2024.1423684.

Exploring the interplay between methylation patterns and non-coding RNAs in non-small cell lung cancer: Implications for pathogenesis and therapeutic targets.

Yang M, Hu X, Tang B, Deng F Heliyon. 2024; 10(2):e24811.

PMID: 38312618 PMC: 10835372. DOI: 10.1016/j.heliyon.2024.e24811.

CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor.

Duan L, Tadi M, Maki C Sci Rep. 2023; 13(1):16271.

PMID: 37759078 PMC: 10533896. DOI: 10.1038/s41598-023-43218-3.

[Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer].

Sun J, Chen J Zhongguo Fei Ai Za Zhi. 2023; 26(1):52-58.

PMID: 36792081 PMC: 9987084. DOI: 10.3779/j.issn.1009-3419.2023.101.03.

References

Turinetto V, Giachino C . Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions. Nucleic Acids Res. 2015; 43(5):2489-98. PMC: 4357700. DOI: 10.1093/nar/gkv061. View

Chastain 2nd P, Brylawski B, Zhou Y, Rao S, Chu H, Ibrahim J . DNA damage checkpoint responses in the S phase of synchronized diploid human fibroblasts. Photochem Photobiol. 2014; 91(1):109-16. PMC: 4303954. DOI: 10.1111/php.12361. View

Bannister A, Kouzarides T . Regulation of chromatin by histone modifications. Cell Res. 2011; 21(3):381-95. PMC: 3193420. DOI: 10.1038/cr.2011.22. View

Kuo L, Yang L . Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo. 2008; 22(3):305-9. View

Kumagai A, Dunphy W . How cells activate ATR. Cell Cycle. 2006; 5(12):1265-8. DOI: 10.4161/cc.5.12.2834. View

Ferry K, Hamilton T, Johnson S . Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000; 60(9):1305-13. DOI: 10.1016/s0006-2952(00)00441-x. View

Usanova S, Piee-Staffa A, Sied U, Thomale J, Schneider A, Kaina B . Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer. 2010; 9:248. PMC: 3098011. DOI: 10.1186/1476-4598-9-248. View

Aggarwal C, Borghaei H . Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Oncologist. 2017; 22(6):700-708. PMC: 5469580. DOI: 10.1634/theoncologist.2016-0345. View

Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

10.

Sanjiv K, Hagenkort A, Calderon-Montano J, Koolmeister T, Reaper P, Mortusewicz O . Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Rep. 2016; 14(2):298-309. PMC: 4713868. DOI: 10.1016/j.celrep.2015.12.032. View

11.

Steuer C, Behera M, Ernani V, Higgins K, Saba N, Shin D . Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA Oncol. 2016; 3(8):1120-1129. DOI: 10.1001/jamaoncol.2016.4280. View

12.

Agger K, Cloos P, Christensen J, Pasini D, Rose S, Rappsilber J . UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007; 449(7163):731-4. DOI: 10.1038/nature06145. View

13.

Hromas R, Williamson E, Fnu S, Lee Y, Park S, Beck B . Chk1 phosphorylation of Metnase enhances DNA repair but inhibits replication fork restart. Oncogene. 2012; 31(38):4245-54. PMC: 3963179. DOI: 10.1038/onc.2011.586. View

14.

Cimprich K, Cortez D . ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008; 9(8):616-27. PMC: 2663384. DOI: 10.1038/nrm2450. View

15.

Basu A, Krishnamurthy S . Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010; 2010. PMC: 2929606. DOI: 10.4061/2010/201367. View

16.

Ezponda T, Dupere-Richer D, Will C, Small E, Varghese N, Patel T . UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Rep. 2017; 21(3):628-640. PMC: 5706555. DOI: 10.1016/j.celrep.2017.09.078. View

17.

Sun Y, Jiang X, Xu Y, Ayrapetov M, Moreau L, Whetstine J . Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol. 2009; 11(11):1376-82. PMC: 2783526. DOI: 10.1038/ncb1982. View

18.

Zheng H, Chen L, Pledger W, Fang J, Chen J . p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression. Oncogene. 2013; 33(6):734-44. PMC: 3912226. DOI: 10.1038/onc.2013.6. View

19.

Zhang Y, Otterness D, Chiang G, Xie W, Liu Y, Mercurio F . Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell. 2005; 19(5):607-18. DOI: 10.1016/j.molcel.2005.07.019. View

20.

Britten R, Liu D, Tessier A, Hutchison M, Murray D . ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000; 89(5):453-7. View